Related Experiment Video
Updated: Dec 25, 2025
Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
Published on: February 8, 2022
Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy
Xianwu Wang1, Shuyao Lang2, Yunpeng Tian3
1Department of Biomaterials, College of Materials, Xiamen University, 422 Siming Nan Road, Xiamen 361005, P. R. China.
Abstract:
Adoptive transfer of immune cells is being actively pursued for cancer treatment. Natural killer (NK) cells, a class of cytotoxic immune cells, generally lack inherent selectivities toward cancer. To bestow tumor-targeting abilities and enhance anticancer efficacy, a new strategy is established to glycoengineer NK cells. Carbohydrate-based ligands for CD22, a marker for B cell lymphoma, are introduced onto NK cells through either metabolic engineering or glyco-polymer insertion. Such NK cells exhibited greatly enhanced cytotoxicities toward CD22+ lymphoma cells in a CD22-dependent manner. Importantly, both CD22+ lymphoma cell lines and primary lymphoma cells from human cancer patients can be effectively killed by the engineered NK cells. Furthermore, glycoengineered NK cells provided significant protection to tumor-bearing mice. Thus, NK cell glycoengineering is an exciting new approach for cancer treatment complementing the current immune cell genetic engineering strategy.
Insights
Glycoengineering Natural Killer (NK) cells enhances their ability to target and destroy cancer cells, particularly B cell lymphoma. This novel approach improves cancer treatment efficacy and offers protection in preclinical models.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Adoptive transfer of immune cells is a promising cancer therapy.
- Natural Killer (NK) cells, while cytotoxic, often lack specific tumor targeting.
- Current strategies for enhancing NK cell efficacy are being explored.
Purpose of the Study:
- To develop a novel strategy for enhancing NK cell anti-cancer activity.
- To engineer NK cells with tumor-targeting capabilities for improved cancer treatment.
Main Methods:
- Glycoengineering of NK cells by introducing CD22-specific carbohydrate ligands.
- Utilized metabolic engineering and glyco-polymer insertion for NK cell modification.
- Assessed cytotoxicity against CD22-positive lymphoma cell lines and primary patient cells.
Main Results:
- Engineered NK cells demonstrated enhanced, CD22-dependent cytotoxicity against lymphoma cells.
- Effectively killed both lymphoma cell lines and primary human lymphoma cells.
- Glycoengineered NK cells provided significant protection in tumor-bearing mouse models.
Conclusions:
- NK cell glycoengineering is a viable strategy to bestow tumor-targeting abilities.
- This approach significantly enhances anti-cancer efficacy against B cell lymphoma.
- Glycoengineering complements existing immune cell-based cancer therapy strategies.
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...